Market Overview:

Bacterial vaccines help prevent various bacterial infections such as pneumococcal disease, meningococcal disease, tuberculosis, tetanus, diphtheria, pertussis (whooping cough), among others. They work by stimulating the body’s immune system to recognize the bacteria as a threat and produce antibodies against it. The major types of bacterial vaccines available in the market are live attenuated vaccines, inactivated vaccines, subunit or conjugate vaccines, toxoid vaccines. They are delivered intramuscularly, orally or intranasally depending on the type of vaccine.

Market Dynamics:

The bacterial vaccines market is primarily driven by the increasing prevalence of bacterial infections worldwide. For instance, according to the World Health Organization (WHO), over 1 million new cases of tuberculosis are reported each year worldwide. In addition, increasing development of combination bacterial vaccine formulations by major market players is also expected to boost the market growth over the forecast period. For example, in January 2023, Emergent BioSolutions Inc. announced FDA approval for a new combination vaccine, Nuvaxovid-BW, which includes components to help protect against COVID-19 virus and two types of bacteria responsible for causing invasive diseases. However, high research and development costs associated with new bacterial vaccine development and lengthy approval process may hamper the market growth.

Segment Analysis
The bacterial vaccines market is segmented into pneumococcal disease, DTP, meningococcal disease, and others. Among them, the pneumococcal disease segment holds the largest market share due to the rising prevalence of the disease globally. According to the WHO, pneumococcal disease causes approximately 826,000 annual deaths globally, especially among children and older adults. This makes pneumococcal disease a dominant sub-segment in the bacterial vaccines market.

PEST Analysis
Political: Government initiatives to increase immunization rates and providing vaccination at low costs are driving market growth. For instance, the Government of India launched the Universal Immunization Program in 1985.
Economic: Rising healthcare expenditure worldwide on prevention and treatment of infectious bacterial diseases is fueling market revenue.
Social: Increasing public-private partnerships to develop affordable bacterial vaccines is positively impacting the market. Growing public awareness on vaccination is another factor.
Technological: Advancements in vaccine production technologies like recombinant DNA, reverse genetics and genomics are enhancing the efficacy and safety of bacterial vaccines.

Key Takeaways

The Global Bacterial Vaccines Market Demand is expected to witness high growth, exhibiting CAGR of 8.0% over the forecast period, due to increasing government focus on immunization programs globally. The market size for bacterial vaccines stood at US$ 23.77 Bn in 2023.

Regional analysis: North America dominates the global bacterial vaccines market owing to supportive reimbursement policies and rising adoption of newly approved bacterial vaccines in the region. However, Asia Pacific is anticipated to register fastest growth in the coming years attributed to increasing healthcare spending in China and India.

Key players: Key players operating in the bacterial vaccines market are GlaxoSmithKline plc, Pfizer Inc., Merck & Co. Inc., Sanofi Pasteur SA, Johnson & Johnson, Serum Institute of India Pvt. Ltd., Bharat Biotech International Limited, Biological E. Limited, Astellas Pharma Inc., Seqirus (CSL Limited), Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Bavarian Nordic, Emergent BioSolutions Inc., Valneva SE.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it